Nicholas Thatcher

Q: What Schools Are Affiliated With Nicholas Thatcher

Nicholas Thatcher is affiliated with the following schools: Imperial College London, University of Oxford, University of Aveiro, University of Manchester, King's College London

Nicholas Thatcher's AcademicInfluence.com Rankings

Nicholas Thatcher

Philosophy

#7419

World Rank

#10632

Historical Rank

Logic

#4468

World Rank

#5767

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Nicholas Thatcher's Degrees

PhD Medical Sciences University of Oxford

Why Is Nicholas Thatcher Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Nicholas Thatcher is Professor of Oncology at the University of Manchester, in the School of Cancer and Imaging Sciences at the Christie Hospital NHS Trust and Wythenshawe Hospital; he was appointed to the position of Professor in 1996. He received his PhD from Manchester University, after prior education at the University of Cambridge and St Bartholomew’s Hospital Medical College, London.

(See a Problem?)

Nicholas Thatcher's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) (2005) (2123)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. (2000) (1187)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. (2006) (736)
Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. (1987) (520)
Alternate splicing produces a novel cyclin D1 transcript. (1995) (448)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. (2006) (430)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. (2015) (402)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. (2014) (400)
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. (1994) (370)
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. (2004) (344)
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome (2000) (332)
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. (2000) (305)
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. (1995) (285)
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. (2010) (261)
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. (1996) (229)
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. (2004) (216)
Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer (2000) (216)
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. (2005) (213)
Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study (2006) (207)
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. (1998) (199)
Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients (1987) (195)
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. (1988) (183)
Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study (2006) (178)
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. (2012) (166)
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (2009) (155)
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. (1986) (153)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. (2004) (152)
Chemotherapy in non-small cell lung cancer. (1995) (141)
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. (1993) (139)
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. (1998) (136)
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data (2006) (133)
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer (2006) (131)
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. (1995) (126)
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer (1999) (121)
Volunteers or victims: patients' views of randomised cancer clinical trials. (1995) (121)
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. (2015) (120)
Where next for gefitinib in patients with lung cancer? (2006) (119)
Epidermal growth factor receptor inhibition in lung cancer: status 2012. (2013) (119)
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. (1990) (118)
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma (2002) (107)
ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (2007) (107)
ACTH precursors characterize the ectopic ACTH syndrome (1994) (107)
Genetic predisposition to human lung cancer. (1986) (102)
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. (2003) (101)
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. (2010) (100)
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. (2005) (96)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. (2012) (95)
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma (2000) (95)
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. (1994) (92)
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK (2015) (90)
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. (1998) (89)
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. (1989) (89)
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. (2017) (89)
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. (2010) (87)
Seroconversion after influenza vaccination in patients with lung cancer (1999) (86)
Malignant melanoma in children and adolescents (1981) (86)
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports (2006) (86)
Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression (1998) (85)
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. (1989) (84)
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. (1989) (83)
Clinicopathologic Features of Advanced Squamous NSCLC. (2016) (80)
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. (2012) (80)
Neurological and cognitive impairment in long-term survivors of small cell lung cancer. (1994) (79)
O6‐(4‐bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts (2000) (79)
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. (1991) (79)
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. (2005) (78)
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma (2003) (76)
Second-Line Treatment of Advanced Non-small Cell Lung Cancer (2008) (73)
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. (1995) (73)
Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial (2013) (73)
Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. (1995) (72)
Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens (2005) (71)
The diagnosis and management of inpatient hyponatraemia and SIADH (2015) (68)
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer (2016) (67)
O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study (2000) (66)
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). (2006) (66)
A method for following human lymphocyte traffic using indium-111 oxine labelling. (1981) (65)
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. (2014) (64)
Epidermal growth factor receptor immunohistochemistry (2008) (62)
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. (1997) (62)
Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer (2006) (61)
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. (1989) (61)
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. (2011) (59)
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. (2013) (59)
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. (1995) (59)
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. (2011) (58)
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. (2008) (58)
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. (1996) (58)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (58)
Haemopoietic cell kinetics in humans treated with rGM‐CSF (1992) (57)
Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. (1992) (57)
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. (1992) (57)
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution (2004) (56)
Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1. (1993) (55)
Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. (1997) (55)
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer (2006) (55)
Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. (1991) (54)
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. (2011) (53)
Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study (2005) (53)
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. (1989) (52)
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. (2009) (51)
G1 control gene status is frequently altered in resectable non‐small cell lung cancer (1997) (51)
Activity of JM9 in advanced ovarian cancer: a phase I-II trial. (1985) (51)
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment (2016) (50)
Melanoma: chemotherapy. (1995) (48)
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. (1998) (48)
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. (1991) (48)
Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2 (1989) (48)
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). (2013) (48)
The value of tumour markers in lung cancer. (1988) (48)
Choroidal metastases from breast carcinoma: a survey of 42 patients and the use of radiation therapy. (1975) (48)
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (2014) (48)
Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. (2005) (48)
Conducting clinical research in the new NHS: the model of cancer (1994) (47)
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. (1988) (47)
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single‐agent carboplatin in patients with poor prognosis small cell lung carcinoma (2001) (47)
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (M (2011) (46)
Dose intensity in cancer chemotherapy. (1990) (45)
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer (2008) (44)
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. (1995) (44)
Lung cancer • 7: Management of lung cancer in elderly patients (2003) (43)
Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. (1981) (42)
Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. (1985) (42)
A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer (2010) (41)
Effect of O6‐(4‐bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model (2002) (41)
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. (2009) (41)
Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis. (1993) (40)
[Breast cancer in the early stage]. (2012) (39)
Preliminary experience with quality of life evaluation in patients with lung cancer. (1990) (39)
Radiotherapy for small-cell lung cancer-Where are we heading? (2009) (39)
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. (2013) (38)
DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. (1990) (38)
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. (2001) (38)
Phase II study of oral topotecan in advanced non-small cell lung cancer. (2000) (37)
Gefitinib for the treatment of non-small-cell lung cancer (2010) (37)
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. (1993) (36)
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5‐fluorouracil, methotrexate, and vitamin A (1980) (35)
Lung cancer after treatment for breast cancer. (2010) (35)
Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. (2004) (34)
A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. (1998) (33)
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study (2019) (33)
Modern Management of Small-Cell Lung Cancer (2012) (33)
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer. (2005) (33)
VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. (1983) (32)
Carboplatin in small cell lung cancer. (1990) (32)
Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. (2003) (31)
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib (2004) (31)
Management of chemotherapy-induced anemia in solid tumors. (1998) (31)
A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. (2005) (31)
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. (2005) (31)
A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). (1989) (31)
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer (1987) (29)
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. (1989) (29)
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. (1994) (29)
Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials (2009) (29)
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. (2012) (29)
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. (1991) (28)
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma (2005) (28)
Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (Stage II) malignant melanoma (1986) (28)
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. (2012) (27)
A simple quantitative HPLC assay for ifosfamide in biological fluids. (1986) (27)
‘Dos and don’ts’ in the management of hyponatremia (2015) (27)
Prevalence of the rhesus‐negative phenotype in caucasian patients with small‐cell lung cancer (SCLC) (1992) (27)
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. (2012) (26)
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. (2000) (26)
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. (2007) (26)
Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. (2008) (26)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (26)
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells (2011) (26)
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. (2009) (26)
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2 (2005) (25)
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. (1993) (25)
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. (1996) (25)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. (2012) (25)
Anti‐T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy—changes in serum levels following C parvum, BCG immunization (1980) (25)
24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC) (1997) (24)
The Migratory Properties of Indium‐111 Oxine Labelled Lymphocytes in Patients with Chronic Lymphocytic Leukaemia (1981) (24)
High‐dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma (1989) (24)
Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. (1994) (24)
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. (1993) (24)
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. (1993) (24)
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. (1997) (24)
Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. (2005) (24)
A clinicopathological study of the paraneoplastic neuromuscular syndromes associated with lung cancer. (1990) (24)
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. (2012) (23)
Biosimilars: what the oncologist should know. (2019) (23)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (23)
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. (1997) (23)
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms (1995) (23)
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. (1991) (23)
Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life (2005) (23)
Clinical Experience with Gefitinib in Indian Patients (2008) (22)
Gemcitabine: once‐weekly schedule active and better tolerated than twice‐weekly schedule (1996) (22)
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results (2002) (22)
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial (2018) (22)
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study (2003) (21)
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. (2011) (21)
Pulmonary carcinoid tumours: a clinico-pathological study of 35 cases. (1986) (21)
Three months' treatment with cyclophosphamide, VP‐16‐213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer (1985) (21)
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. (1977) (20)
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. (2005) (20)
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. (1990) (20)
DNA analysis by flow cytometry in malignant pleural mesothelioma: Relationship to histology and survival (1990) (20)
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients (2004) (20)
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer (2010) (20)
The effect of age on the pharmacokinetics of ifosfamide. (1990) (20)
The place of targeted therapy in the patient management of non-small cell lung cancer. (2007) (20)
Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions. (1979) (19)
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump (2005) (19)
A retrospective study of thirty-two patients with small-cell bronchogenic carcinoma and inappropriate secretion of antidiuretic hormone. (1986) (19)
Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable Prognosis (2007) (19)
Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. (1995) (18)
Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer -- a pilot study. (2002) (18)
Intermittent high‐dose cyclophosphamide with and without prednisolone. A study of the relationships between toxicity, response and survival in metastatic lung cancer (1982) (18)
Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. (1991) (18)
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts (2000) (18)
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial (2016) (18)
Origins of hepatomegaly produced by dexamethasone (DEX), pregnenolone 16 alpha-carbonitrile (PCN) and phenobarbitone (PB) in female Sprague-Dawley rats. (1994) (17)
Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2. (1993) (17)
A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE) (1994) (17)
A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. (1993) (17)
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study) (2010) (17)
Survival improvement in thoracic cancer: progress from the last decade and beyond. (2007) (17)
Turner's syndrome with coeliac disease, thin bones and abnormal liver function tests (1973) (16)
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study (2017) (16)
Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. (1994) (16)
Etoposide infusions for treatment of metastatic lung cancer. (1984) (16)
11-WEEK COURSE OF SEQUENTIAL METHOTREXATE, THORACIC IRRADIATION, AND MODERATE-DOSE CYCLOPHOSPHAMIDE FOR "LIMITED"-STAGE SMALL-CELL BRONCHOGENIC CARCINOMA A Study from the Manchester Lung Tumour Group (1982) (16)
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non‐small cell lung cancer. From the Manchester Lung Tumour Group (1988) (16)
Erlotinib in non-small cell lung cancer: a review (2005) (15)
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. (1985) (15)
O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data (2003) (15)
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. (2008) (15)
Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. (1995) (14)
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small‐Cell Lung Cancer (2017) (14)
Options for first- and second-line therapy in small cell lung cancer--a workshop discussion. (2003) (14)
Analysis of the glutathione conjugate of paracetamol in human liver microsomal fraction by liquid chromatography mass spectrometry. (2001) (14)
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) (2016) (14)
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view (2008) (14)
Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC). (2009) (14)
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. (1991) (14)
Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. (1994) (14)
Novel Therapies for the Treatment of Small-Cell Lung Cancer (2012) (13)
Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) (2008) (13)
Chemotherapy for advanced lung cancer. (2004) (13)
The effect of route of administration and fractionation of dose on the metabolism of ifosfamide (2008) (13)
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration (2002) (13)
Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC. (2016) (13)
Targeting blood vessels for the treatment of non-small cell lung cancer. (2008) (13)
A phase I and pharmacokinetic study of amphethinile. (1988) (13)
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer (2007) (13)
In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with ma (2004) (12)
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. (2005) (12)
Tamoxifen in the treatment of metastatic malignant melanoma. (1982) (12)
Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. (1986) (12)
Brampton, M, Stevens MFG. Cancer Research Campaign phase-II trial of temozolomide in malignant melanoma (1995) (12)
Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung. (1995) (12)
Ifosfamide/carboplatin/etoposide (ICE) regimen in small cell lung cancer (1993) (12)
Consensus on medical treatment of non-small cell lung cancer. (2002) (12)
Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma. (1989) (12)
The feasibility of using glycosylated recombinant human granulocyte colonystimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin; cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer (1995) (11)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 ( TLR 9 agonist ) as first-line treatment of advanced non-small-cell lung cancer (2011) (11)
Targeted molecular mechanisms of epoetin alfa. (2003) (11)
Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial. (2004) (11)
Dose intensity in small cell lung cancer. (1998) (11)
O-275 Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21) (2003) (11)
Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial (2017) (11)
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. (1991) (11)
The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. (2013) (10)
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. (2003) (10)
9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390) (2009) (10)
Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non–Small Cell Lung Cancer (2005) (10)
Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer. (1984) (10)
Management of small-cell lung cancer. (2004) (10)
Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. (1991) (10)
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? (2019) (10)
Intensive combined-modality therapy in small cell lung cancer. (1994) (10)
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. (1997) (10)
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease (2004) (10)
EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): necitumumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC (2015) (10)
Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. (1979) (10)
Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes. (1994) (10)
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party. (1995) (9)
Serum glycoprotein hormone alpha sub-unit values and survival in metastatic melanoma patients. (1979) (9)
Management of elderly patients with lung cancer (2000) (9)
Changes in cellular immunity following nephrectomy for localized and metastatic hypernephroma. (1977) (9)
P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies (2003) (9)
Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. (1989) (9)
G- and GM-CSF. (1998) (9)
Aggressive vs nonaggressive therapy for metastatic NSCLC. (1996) (9)
Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions. (1979) (9)
Epidermal Growth Factor Receptor Inhibition in Lung Cancer (2013) (9)
Adjuvant interferon in melanoma – a resurrection? (2001) (9)
Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days (1981) (9)
Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor (1992) (8)
Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients. (1982) (8)
Concise manual of hematology and oncology (2008) (8)
Perspectives on novel therapies for bronchial carcinoma (2005) (8)
87 Effects of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC); results of UKCCCR/EORTC randomised trial (1995) (8)
Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC). (1996) (8)
Chemotherapy for advanced non-small cell lung cancer. (2001) (8)
Constitutional frequencies of c-Ha-ras alleles in patients with different types of lung cancer. (1990) (8)
Current status of quality of life measurement in lung cancer patients. (1991) (8)
Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study. (1989) (8)
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. (1991) (8)
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. (2019) (8)
The “Hot spleen” phenomenon in metastatic malignant melanoma. Its incidence and relationship with the immune system (1982) (8)
9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer (2009) (8)
Bioavailability of ifosfamide in patients with bronchial carcinoma (2004) (8)
Antivascular agents for non-small-cell lung cancer: current status and future directions (2009) (8)
New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment. (1992) (8)
Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. (1996) (8)
Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma (2004) (8)
Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man. (1979) (7)
Treatment of metastatic melanoma by 24‐hour DTIC infusions and hemibody irradiation (1986) (7)
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. (1988) (7)
Lymphocyte function in the blood of patients with untreated non-Hodgkin lymphoma: influence of stage and pathology. (1977) (7)
Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue (2004) (7)
Blood clearance of three radioactively labelled platinum complexes, in patients with malignant disease. (1982) (7)
A method for studying the dynamics of the primary migration of human lymphocytes using Indium-iii oxine cell labelling. (1982) (7)
Dacarbazine and interferon‐α 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations (1995) (7)
Clinical applications of myeloid colony stimulating factors. (1990) (7)
9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390) (2009) (7)
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. (1990) (7)
PD-066 Does reporting expected duration and severity of adverseevents provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel (2005) (6)
Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group (2012) (6)
Use of rHuG-CSF (lenograstim) to dose intensify in small cell lung cancer (SCLC): A randomised study (1993) (6)
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. (2011) (6)
Palliative treatment. (2004) (6)
A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer. (1986) (6)
9009 A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC) (2009) (6)
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies. (1990) (6)
Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. (1977) (6)
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump: an HPLC-dynamic FAB study. (1993) (6)
Ifosfamide by bolus as treatment for advanced non-small cell lung cancer (2004) (6)
Integrating new targeted agents into the treatment of non-small-cell lung cancer. (2006) (6)
Where next for gefi tinib in patients with lung cancer (2006) (6)
A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. (2003) (5)
Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
Gefitinib or docetaxel in advanced non-small-cell lung cancer (2008) (5)
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial (2007) (5)
103PDSUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC) (2015) (5)
Paclitaxel: a hope for advanced non-small cell lung cancer? (1999) (5)
Growth factor-assisted chemotherapy--the Manchester experience. (1990) (5)
Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC) (2016) (5)
Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introduction. (2004) (5)
Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC) (1996) (5)
6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390) (2007) (5)
Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer (2012) (5)
Management of unresectable non-small cell carcinoma of the lung (NSCLC). (2003) (5)
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump (2004) (5)
Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. (1992) (5)
Current trends in prophylactic cranial irradiation (PCI) for extensive-disease small cell lung cancer (EDSCLC): Results of a UK survey (2008) (4)
Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations. (1979) (4)
Immunoscintigraphy with 99mTc labelled F(ab′)2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma (2004) (4)
Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC) (2007) (4)
Clinical applications of interleukin-2. (1992) (4)
A phase I toxicity study of human rDNA interferon in patients with solid tumours (2004) (4)
Phase II study of vindesine infusion in visceral metastatic malignant melanoma. (1983) (4)
Cytogenetic effects of antitumour drugs in man in vivo (1980) (4)
Management of the solitary metastasis. (1990) (4)
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. (2018) (4)
Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer (NSCLC). (2004) (4)
Commentary on ZD1839 (Iressa) in non small cell lung cancer. (2003) (4)
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party. (1995) (4)
The importance of dose and schedule in chemotherapy for small cell lung cancer (1995) (4)
P-574 Randomised phase 3 trial of autologous blood progenitor cell and filgrastim supported dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) — a different toxicity profile (2003) (4)
P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer (2005) (3)
Novel approaches with ifosfamide in small cell lung cancer. (1992) (3)
Dose Dense chemotherapy supported by whole-blood haematopoietic progenitors in better prognosis small cell lung cancer (2005) (3)
The Influence of Sex in Non-Small Cell Lung Cancer (2009) (3)
19 First results of a randomised trial of dose intensification (DI) with G-CSF in small cell lung cancer (SCLC) (1997) (3)
A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): Update on quality of life (QoL), toxicity, and costs (2005) (3)
267 Tolerability of dose-intensive ICE chemotherapy for SCLC with filgrastim and reinfusion of haemopoietic progenitors in whole blood (1997) (3)
9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study (2009) (3)
A phase III randomised study of carboplatin and amifostine (A) vs carboplatin and G-CSF in patients with inoperable non small cell lung cancer (NSCLC) (1997) (3)
1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS. (2014) (3)
Upper abdominal lymphadenopathy as first presentation of relapse, identified by ultrasonography, in patients treated for small cell (oat cell) bronchogenic carcinoma. (1985) (3)
Long-term toxicity report from a phase II study of accelerated twice-daily (BD) versus high dose once-daily (OD) thoracic radiotherapy (RT) with concurrent chemotherapy for limited stage small cell lung cancer (LS-SCLC) (2011) (3)
Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of three consecutive randomized trials. (2006) (3)
Cumulative Exposure (EXP) to Bevacizumab (BV) Maintenance after Induction Therapy and Survival in Advanced Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis from the Sail (MO19390) Study (2012) (3)
The ISEL and BR21 trials – Outcomes similar or different? (2006) (3)
Chemotherapy in the management of invasive bladder cancer (1979) (3)
Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC). (2015) (3)
42 Updated results of a randomised trial confirm that oral etoposide alone is inadequate palliative chemotherapy (CT) for small cell lung cancer (SCLC) (1997) (3)
Chemotherapy for symptom control in advanced NSCLC (1997) (3)
Relationship between 06-alkylguanine-DNA alkyltransferase levels and 06-methyldeoxyguanosine formation in peripheral blood cells of patients receiving CBI0-277. (1994) (3)
Phase I clinical trial of methylene dimethane sulfonate. (1987) (3)
Bioavailability of ifosfamide in patients with bronchial carcinoma. (1986) (3)
Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin. (1981) (3)
Effects of diagnostic method and surgery on safety of first-line bevacizumab plus chemotherapy in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) (2008) (3)
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide (2008) (2)
A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent. (1983) (2)
Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited stage small cell lung cancer (LS-SCLC) (2008) (2)
Chemotherapy in non-small cell lung cancer. Discussion (1995) (2)
Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data? (2008) (2)
Maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the Phase III SQUIRE study. (2015) (2)
Rash as a marker for the efficacy of necitumumab in the SQUIRE Study (2015) (2)
Multicentric reticulohistiocytosis (1987) (2)
Interleukin 2: Clinical Aspects (1990) (2)
B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemicitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration (2007) (2)
Formation and loss of 06-methyldeoxyguanosine (06-MedG) in peripheral leukocytes of patients receiving dacarbazine (DTIC) or CB 10-277. (1993) (2)
Second IASLC Workshop on combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Treatment evaluation. (1994) (2)
Update on targeted therapies for small cell carcinoma of the lung (2008) (2)
Filgrastim with dose intensified CDE chemotherapy in small cell lung cancer (1993) (2)
A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results. (2004) (2)
Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy. (1978) (2)
A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion (2004) (2)
Omitting elective nodal irradiation (ENI) during thoracic irradiation in limited-stage small cell lung cancer (LS-SCLC) Patterns of failure from a phase II trial (2010) (2)
New drugs in small cell lung cancer. (2002) (2)
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). (1993) (2)
Blood clearance of radioactively labelled CBDCA in cancer patients. (1983) (2)
Sequential administration of dacarbazine and fotemustine in disseminated melanoma (1991) (2)
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer (2004) (2)
P3-078: MO19390: an open-label safety study of bevacizumab in combination with chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) (2007) (1)
Outcome of prophylactic cranial radiotherapy in extensive-stage small cell lung cancer: The christie experience over two years (2010) (1)
O-90 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable advanced non-small cell lung cancer (NSCLC) — A British thoracic oncology group (BTOG) trial (2003) (1)
1267PQUALITY-OF-LIFE (QOL), TOLERABILITY, AND SUPPORTIVE CARE RESULTS: NECITUMUMAB PHASE 3 SQUIRE STUDY. (2014) (1)
80 Dose-intensification of V-ICE chemotherapy with GM-CSF in small cell lung cancer (SCLC)—A prospective randomised study of 301 patients (1995) (1)
136 Single centre phase II trial of paclitaxel (Taxol) administered as a 3 hour infusion in patients with advanced non small cell lung cancer (NSCLC) (1997) (1)
Expression ofepidermal growth factor receptor (EGF-R)innon-small cell lung cancer.Useofarchival tissue andcorrelation ofEGF-Rwith histology, tumoursize, nodestatus andsurvival (1989) (1)
234 Reduction of the risk of transfusion in patients with small cell lung cancer (SCLC) undergoing chemotherapy (1995) (1)
Lymphocyte Cytotoxicity in Melanoma Patients Undergoing Immunotherapy (1979) (1)
Response to Comments on “No Study Left Behind: A Network Meta-Analysis in Non-Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”: Letter to the Editor (2010) (1)
In vivo distribution studies of radioactively labelled platinum complexes in patients with malignant disease, using a gamma-camera. (1985) (1)
Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) (2016) (1)
Single dose prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) (1991) (1)
Effects of intermittent 5-fluorouracil and adriamycin on various immune parameters in carcinoma patients with reference to the tumour load (1977) (1)
The Value of Erythropoietin Therapy in Cancer Patients (2005) (1)
Combination treatment with Interleukin-2 and chemotherapeutic agents (1993) (1)
A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status (2006) (1)
Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE) (2014) (1)
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study (2019) (1)
Commitment demanded for lung cancer research. (1995) (1)
Clostridial myonecrosis in association with etoposide therapy presenting as severe thigh pain. (1986) (1)
Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC). (2016) (1)
MO19390 (SAiL): Incidence of hemorrhage with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). (2016) (1)
Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. (2000) (1)
Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study. (2015) (1)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (1)
Treatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'. (1994) (1)
P2.13-40 ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE) (2018) (1)
Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: Pharmacokinetic results and justification for extrapolation across bevacizumab indications. (2017) (1)
Chemotherapy in metastatic melanoma (1995) (1)
Sequential DTIC and fotemustine in the treatment of metastatic melanoma. (1991) (1)
Abstracts of the 8th International Conference of the International Mesothelioma Interest Group. October 19-22, 2006. Chicago, Illinois, USA. (2006) (1)
Dose intensity in small-cell lung cancer (SCLC) (1997) (1)
CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA (2010) (1)
The Manchester Experience with Ifosfamide and Mesna in Lung Cancer (1989) (1)
Precursor synthesis towards the development of [124I]‐labelled 2′, 2′‐difluoro‐2′‐deoxycytidine as a potential pet radiotracer for the anticancer drug gemcitabine (2001) (1)
Phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC) (2000) (1)
Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics. (2007) (1)
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. (2006) (1)
Chemotherapy and quality of life in advanced NSCLC – reply (2001) (1)
The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours (2016) (1)
Ifosfamide, etoposide and thoracic radiotherapy for small cell lung cancer (1986) (1)
Changes in nonspecific lymphoid (NK, K, T cell) cytotoxicity following BCG immunisation of healthy subjects (2004) (1)
Elevated serum alpha subunit levels in patients with cancer; a consequence of gonadotrophin secretion and age. (1987) (1)
Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study (2015) (1)
Ef fi cacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non – small Cell Lung Cancer ( MAPLE ) : A Randomized , Double-blind , Phase III Study (2019) (1)
Clinical prognostic factors in advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients treated in three consecutive randomized trials (2007) (0)
Alkylating agents (2014) (0)
O-153 Phase III randomised trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients (2005) (0)
6IN SCLC CONSENSUS (2011) (0)
Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study. (2019) (0)
330 Adjuvant chemotherapy should not be given in NSCLC (2003) (0)
The management of lung cancer in the elderly (1996) (0)
Lymphohaematopoietic Growth Factor Use in Lung Cancer Patients (1992) (0)
Dacarbazine, BCNU, cisplatin and tamoxifen (DBCT) v dacarbazine and interferon (DTIC/Ifn) in advanced melanoma: results of a randomised phase lll study. (1998) (0)
Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients (2005) (0)
Comprar Concise Manual of Hematology and Oncology | Andreeff, Michael | 9783540732761 | Springer (2008) (0)
Lung cancer c 7: Management of lung cancer in elderly patients (2003) (0)
The Management of Weakness and Fatigue in Solid Tumours (2003) (0)
The toxicity of cancer chemotherapy in adults (1988) (0)
Can Beta Tubulin Mutations Detected in Serum DNA Predict for Docetaxel Resistance in Advanced Non-Small Cell Lung Cancer (2002) (0)
Alkylation of lymphocyte DNA during chemotherapy with DTIC. (1991) (0)
Treatment of advanced metastatic melanoma -some new approaches with chemotherapy and interleukin 2 (IL-2): 115 (1993) (0)
RAS P21 oncogene in bronchopulmonary carcinoids and bronchogenic carcinoma. (1991) (0)
Cetuximab in non-small cell lung cancer (2012) (0)
P-26 Phase II trial with RFS 2000 (9NC) in patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) (2003) (0)
Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel (2005) (0)
Not breathing easier. (1998) (0)
A consensus guideline for management of erlotinib-associated cutaneous toxicity in the UK (2008) (0)
P2-298: Report on three consecutive randomized phase II trials using single-agent docetaxel and gemcitabine in diferent doses and schedules for patients in advanced non-small cell lung cancer (NSCLC) (2007) (0)
A single institution experience of adjuvant chemotherapy for resected NSCLC (2010) (0)
Final efficacy and safety results of ECOG Performance Status (PS) subgroup analyses from the SQUIRE phase III study (2015) (0)
Summary of trials involving high dose IL-2 in patients with advanced melanoma: 407 (1997) (0)
Variant xeroderma pigmentosum group D polymorphisms predict for survival in patients with advanced NSCLCreceiving platinum based chemotherapy (2004) (0)
P2-252: Analyses of clinical prognostic factors in the treatment of advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients from three consecutive randomized Phase II trials using gemcitabine and docetaxel (2007) (0)
High dose ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer (1992) (0)
DNA methylation and clinical response following alkylating agent chemotherapy for malignant melanoma. (1992) (0)
OA23.02 Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study (2017) (0)
Dose intensification in small cell lung cancer chemotherapy (1998) (0)
Antivascularagentsfor non-small-celllungcancer: currentstatusandfuturedirections (2009) (0)
The Management of Weakness and Fatigue in Patients with Solid Tumours (2003) (0)
Muscle Weakness and Lung Carcinoma (1985) (0)
53 Pemetrexed based chemotherapy for malignant mesothelioma; a retrospective analysis of 100 consecutively treated patients (2007) (0)
Multicentre phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC) (2000) (0)
Immunostimulation: Edited by Louis Chedid (232 pp). Vol. 2 Nos. 1 and 2 in Springer Seminars in Immunopathology (P.A. Miescher and H.J. Mueller-Eberhard, Series editors). Springer International, 1979. (1980) (0)
P-753 Extrapulmonary small cell carcinoma: Our experience over ten years (2005) (0)
Haematopoietic growthfactors andlungcancer treatment (1992) (0)
Supplementary Material for: Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) (2016) (0)
06-Alkylguanine-DNA Alkyltransferase Depletion and Regeneration in Human Peripheral Lymphocytes following Dacarbazine and Fotemustine 1 (2006) (0)
Intensive chemotherapy in the management of small cell lung cancer (1998) (0)
Editorial-Adjuvant interferon in melanoma – a resurrection? (2017) (0)
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump (2008) (0)
The Effect of Recombinant Human Erythropoietin in Anaemic Lung Cancer Patients (2005) (0)
Treatment of small cell lung carcinoma in association with cryptogenic fibrosing alveolitis (1982) (0)
Age-Stratified Subgroup Analysis of SQUIRE in Patients With Stage IV Squamous NSCLC (2015) (0)
An Analysis of the Influence of Sex and Histology on Outcomes in Non-Small Cell Lung Cancer (2009) (0)
Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited-stage small cell lung cancer (LS-SCLC) (2009) (0)
196 A phase III randomised study of amifostine vs G-CSF to prevent the myelotoxicity of carboplatin chemotherapy in non-small cell lung cancer (NSCLC) (1997) (0)
Blood clearance of radio-labelled Cis-diamine-1, 1-cyclobutane dicarboxylato platinum (11)(CBDCA) (1983) (0)
European School of Oncology First Euro-American Forum Treatment on Lung Cancer (2003) (0)
Some clinical concepts in small cell lung cancer (2005) (0)
P2.03b-035 EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE: Topic: Biomarkers (2017) (0)
Small Cell Lung Cancer (SCLC); any progress? (2007) (0)
P-404 Does transforming growth factor-beta1 codon 25 polymorphismgenotype influence tumour histology or patient survival in malignant pleural mesothelioma? (2005) (0)
CASEREPORTS Turner's syndrome withcoeliac disease, thin bones andabnormal liver function tests (1973) (0)
Randomized study of Cornybacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma (1987) (0)
Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma (2000) (0)
DNA Repair & Cisplatin Resistance (2003) (0)
E-81.Small cell lung cancer- treatment strategies in the elderly and poor performance status patients (2003) (0)
Tarceva in relapsed non-small cell lung cancer: experience from Northwest England (2008) (0)
PD4-3-2: Observing who performance status of patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC) (2007) (0)
Response to ‘How we define hyponatremia?’ (2015) (0)
122 Small cell lung carcinoma: experience in patients treated with initial chemotherapy or sequential chemotherapy plus radiotherapy 2005–2010 (2011) (0)
Evaluating the safety of using G-CSF prophylaxis during concurrent thoracic chemo-radiotherapy (CTRT) in patients with limited-disease small-cell lung cancer (LD-SCLC): Evidence from a phase II trial (2010) (0)
O-102 Gemcitabine and docetaxel as concomitant or sequential first-linetherapy of advanced non-small cell lung cancer: Updated results of a randomized study (2005) (0)
Gene therapy of cancer: Reality and perspectives of poor long term operable breast In Inoperable non-small cell lung cancer (NSCLC) (2005) (0)
In vivo depletion of human 06-alkylguanine-DNA alkyltransferase by temozolomide. (1994) (0)
Observation of survival and its prognostic factors in patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC): A3-02 (2007) (0)
A phase-II study of ifosfamide and alpha-2 interferon (intron-A) in advanced non-small cell lung-cancer (1990) (0)
Comparison of epidermal growth factor receptor expression in lung cancer by immunohistochemical staining of both frozen and formalin fixed specimens. (1991) (0)
Blood clearance of radiolabelled CBDCA (1983) (0)
Monoclonal antibodies against the epidermal growth factor receptor (1986) (0)
O-37 An analysis of the value of immunohistochemistry in differentiating between mesothelioma and pulmonary adenocarcinoma involving the pleura (2003) (0)
Human lymphocyte trafic assessed by In-111 oxide labelling: clinical observation. (1981) (0)
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer (2005) (0)
Bioavailability of Ifosfamide in Lung Cancer Patients1 (1987) (0)
The expanding role of systemic treatment in NSCLC (2006) (0)
Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC). (2017) (0)
Malignant: Anti-T antibody in malignant melanoma patients (1981) (0)
Current practice and upcoming topics in treatment individualization of advanced non-small cell lung cancer (2012) (0)
P-505 The North West Lung Centre experience of malignant pleural mesothelioma 1980–2000 (2003) (0)
The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC). (2002) (0)
Updated on targeted therapy for SCLC (2011) (0)
811 'Flu vaccination in lung cancer patient — Is it effective? (1997) (0)
810 A multi-centre trial of nursing management of dyspnoea — One centre's experience (1997) (0)
P-511 Atypical presentation, patterns of disease progression and long term survival in malignant pleural mesothelioma (2003) (0)
1058 A phase II evaluation of bone marrow protection by ethyol® (Amifostine)(Am) in patients with non-small cell lung cancer (NSCLC) treated with carboplatin(c) (1995) (0)
P2.03a-025 Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC: Topic: Clinical Trials (2017) (0)
Phase II Study of Continuous Subcutaneous Interferon-Alfa Combined with Cisplatin in Advanced Malignant Melanoma (1992) (0)
Editorial Comment Chemotherapy for advanced lung cancer (2004) (0)
Phase II trial of 4-hourly temozolomide (TMZ) in advanced malignant melanoma (MM) (1999) (0)
Advanced and metastatic treatment of non-small cell lung cancer (2012) (0)
High-dose chemotherapy of solid tumours. Discussion (1995) (0)
Relationship between 06-alkylguanine-DNA-alkyltransferase activity and 06-methyldeoxyguanosine formation after treatment with methylating agents in patients with malignant melanoma. (1993) (0)
Toxicity of temozolomide with response modifiers in metastatic malignant melanoma (2002) (0)
Observing patients with advanced non-small cell lung cancer (NSCLC): An overview of real world treatments and outcomes in Europe (2016) (0)
Randomized P hase I I S tudy o f T emozolomide G iven E very 8 Hours o r D aily W ith E ither I nterferon A lfa-2b o r T halidomide in M etastatic M alignant M elanoma (2003) (0)

This paper list is powered by the following services:

Other Resources About Nicholas Thatcher

en.wikipedia.org

What Schools Are Affiliated With Nicholas Thatcher?

Nicholas Thatcher is affiliated with the following schools:

Nicholas Thatcher's Academic­Influence.com Rankings